美國生物技術大會暨展覽會（BIO International Convention）創辦于1993年，是美國生物技術創新組織的年會，也是全球規模最大、專業性最強、影響力最廣的生物技術盛會。2024 BIO將于2024年6月3日-6日（EDT）于美國加利福尼亞州圣地亞哥會展中心舉辦。翌圣鎂孚泰生物CEO劉想博士，翌圣生物副總裁宋東亮博士將攜公司技術團隊在現場與來自全球生物行業的領軍人物共同探討生物技術領域的創新成果與行業趨勢，并尋求具有廣闊發展空間的商業合作機會。
參展信息
時間：2024年6月3日-6日（EDT）
地點：美國加利福尼亞州圣地亞哥展覽中心
展號： 4507（中國館）-15號展位
聯系人：+86 13651753995
翌圣鎂孚泰生物屆時將攜創新酶進化技術&服務、T7 RNA polymerase改造等最新研究成果參加本次展會，我們期待與您相聚，共襄盛舉！
精彩預告
Molefuture Biotechnology, a subsidiary of Yeasen Biotechnology (Shanghai) Co., Ltd., specializes in tailored enzyme modification solutions driven by cutting-edge enzyme evolution technologies. These solutions cater to diverse application needs in areas such as in vitro diagnostics, biopharmaceuticals, synthetic biology, medical aesthetics, pharmaceutical intermediates, and beyond.
ZymeEditor enzyme evolution platform
The ZymeEditor platform seamlessly integrates directed evolution and rational design techniques. It autonomously incorporates cutting-edge enzyme evolution technologies, including Fluorescence-Activated Droplet Sorting (FADS), alongside traditional methods like Microtiter Plate Screening (MTPS) and forfront Computer-Aided Rational Design (CARD). Through cross-screening utilizing these technologies, ZymeEditor significantly enhances the efficacy of enzyme evolution, leading to the optimization of various enzyme properties such as activity, stability, selectivity, and more.
UCF·METM ultra-clean purification platform
To address the growing need for large-scale production of top-quality enzymes, Molefuture, supported by its parent company Yeasen, has erected two GMP-compliant production facilities spanning nearly 10,000 square meters in Wuhan, China. Additionally, we've installed two state-of- the-art, fully automated 1500-liter fermentation systems and assembled a dedicated team of experts specializing in enzyme production and quality assurance. These resources collectively ensure the successful scale-up production of high-caliber enzymes.
Case Studies
1. Reducing T7 RNA polymerase dsRNA by-products
1) ELISA for dsRNA content shows that mutants M1-5 have lower dsRNA levels, with M5 reducing by 98% compared to WT and 78% compared to a competitor (Fig 3- a).
2) Dot blot analysis confirms that mutants M1-5 have reduced dsRNA content (Fig 3-b)
2. Enhancing stability and reducing adapter-adapter ligation of T4 DNA Ligase
1) By protein engineering, the stability of T4 DNA ligase mutants increased significantly without sacrificing their activity. M6 could keep its activity 100% under 45 degree(Fig 2).
2) The Qseq tests showed that the adapter-adapter ligation ratio of the mutants decreased from 10% of the wild type to about 3%, and even lower to 1% of M1 and M4(Fig 3).
3) After incubation at 42℃ for 1h, the DNA yields of mutants increased dramatically in Preparation of DNA Libraries(Fig 4).